Conference Coverage

Prolia tops risedronate at 2 years in steroid-induced osteoporosis

Publish date: July 10, 2018

 

REPORTING FROM THE EULAR 2018 CONGRESS

SOURCE: Saag KG et al. Ann Rheum Dis. 2018;77(Suppl 2):218. Abstract OP0345.

Pages

Recommended Reading

Time to take the fear out of the hormone therapy conversation
MDedge Internal Medicine
VIDEO: Dr. Andrew Kaunitz’s top lessons from NAMS 2017
MDedge Internal Medicine
Use of opioids, SSRIs linked to increased fracture risk in RA
MDedge Internal Medicine
Transgender women on HT have lower bone density, more fat mass than men
MDedge Internal Medicine
Spine fracture risk may be increased in IBD patients
MDedge Internal Medicine
Original research expands at AACE 2018
MDedge Internal Medicine
AACE 2018: A dream team of presenters
MDedge Internal Medicine
VIDEO: BMI helps predict bone fragility in obese patients
MDedge Internal Medicine
FDA approves Prolia for glucocorticoid-induced osteoporosis
MDedge Internal Medicine
Bisphosphonate ‘holidays’ exceeding 2 years linked to increased fractures
MDedge Internal Medicine